Cerebrospinal Fluid Protein Biomarkers for Alzheimer's Disease

Overview

Journal NeuroRx

Specialty Neurology

Date 2005 Feb 18

PMID 15717022

Citations 185

Authors

Kaj Blennow

Affiliations

Soon will be listed here.

Abstract

The introduction of acetylcholine esterase (AChE) inhibitors as a symptomatic treatment of Alzheimer's disease (AD) has made patients seek medical advice at an earlier stage of the disease. This has highlighted the importance of diagnostic markers for early AD. However, there is no clinical method to determine which of the patients with mild cognitive impairment (MCI) will progress to AD with dementia, and which have a benign form of MCI without progression. In this paper, the performance of cerebrospinal fluid (CSF) protein biomarkers for AD is reviewed. The diagnostic performance of the three biomarkers, total tau, phospho-tau, and the 42 amino acid form of beta-amyloid have been evaluated in numerous studies and their ability to identify incipient AD in MCI cases has also been studied. Some candidate AD biomarkers including ubiquitin, neurofilament proteins, growth-associated protein 43 (neuromodulin), and neuronal thread protein (AD7c) show interesting results but have been less extensively studied. It is concluded that CSF biomarkers may have clinical utility in the differentiation between AD and several important differential diagnoses, including normal aging, depression, alcohol dementia, and Parkinson's disease, and also in the identification of Creutzfeldt-Jakob disease in cases with rapidly progressive dementia. Early diagnosis of AD is not only of importance to be able to initiate symptomatic treatment with AChE inhibitors, but will be the basis for initiation of treatment with drugs aimed at slowing down or arresting the degenerative process, such as gamma-secretase inhibitors, if these prove to affect AD pathology and to have a clinical effect.

Citing Articles

Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease.

Safransky M, Groh J, Blennow K, Zetterberg H, Tripodis Y, Martin B Neurology. 2024; 103(11):e209866.

PMID: 39496102 PMC: 11540457. DOI: 10.1212/WNL.0000000000209866.

Osteopontin: A novel marker of pre-symptomatic sporadic Alzheimer's disease.

Quesnel M, Labonte A, Picard C, Bowie D, Zetterberg H, Blennow K Alzheimers Dement. 2024; 20(9):6008-6031.

PMID: 39072932 PMC: 11497655. DOI: 10.1002/alz.14065.

Unveiling the Complex Role of Exosomes in Alzheimer's Disease.

Sun M, Chen Z J Inflamm Res. 2024; 17:3921-3948.

PMID: 38911990 PMC: 11193473. DOI: 10.2147/JIR.S466821.

The clinical importance of suspected non-Alzheimer disease pathophysiology.

Vos S, Delvenne A, Jack Jr C, Thal D, Visser P Nat Rev Neurol. 2024; 20(6):337-346.

PMID: 38724589 DOI: 10.1038/s41582-024-00962-y.

Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.

Garcia-Cordero I, Anastassiadis C, Khoja A, Morales-Rivero A, Thapa S, Vasilevskaya A Ann Neurol. 2024; 96(1):99-109.

PMID: 38578117 PMC: 11249787. DOI: 10.1002/ana.26930.

References

Buerger K, Teipel S, Zinkowski R, Blennow K, Arai H, Engel R . CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002; 59(4):627-9. DOI: 10.1212/wnl.59.4.627. View

Haass C, Selkoe D . Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 1993; 75(6):1039-42. DOI: 10.1016/0092-8674(93)90312-e. View

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. DOI: 10.1001/archneur.56.6.673. View

Monte S, Ghanbari K, Frey W, Beheshti I, Averback P, Hauser S . Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest. 1998; 100(12):3093-104. PMC: 508522. DOI: 10.1172/JCI119864. View

Wallin A, Sjogren M, Blennow K, Davidsson P . Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord. 2003; 16(4):200-7. DOI: 10.1159/000072803. View

Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F . CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci. 2001; 22(1):77-8. DOI: 10.1007/s100720170055. View

Hershko A, Ciechanover A . The ubiquitin pathway for the degradation of intracellular proteins. Prog Nucleic Acid Res Mol Biol. 1986; 33:19-56, 301. DOI: 10.1016/s0079-6603(08)60019-7. View

Buerger K, Zinkowski R, Teipel S, Tapiola T, Arai H, Blennow K . Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002; 59(8):1267-72. DOI: 10.1001/archneur.59.8.1267. View

Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K . Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003; 15(3):169-76. DOI: 10.1159/000068478. View

10.

Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K . Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative study. J Neural Transm (Vienna). 2001; 107(4):463-78. DOI: 10.1007/s007020070088. View

11.

Sjogren M, Davidsson P, Wallin A, Granerus A, Grundstrom E, Askmark H . Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord. 2002; 13(2):112-8. DOI: 10.1159/000048642. View

12.

Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M . Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997; 148(1):41-5. DOI: 10.1016/s0022-510x(96)00314-0. View

13.

Andreasen N, Gottfries J, Vanmechelen E, Vanderstichele H, Davidson P, Rosengren L . Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001; 71(4):557-8. PMC: 1763527. DOI: 10.1136/jnnp.71.4.557. View

14.

Sunderland T, Linker G, Mirza N, Putnam K, Friedman D, Kimmel L . Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003; 289(16):2094-103. DOI: 10.1001/jama.289.16.2094. View

15.

Gross J, Carlson R, Brauer A, Margolies M, Warshaw A, Wands J . Isolation, characterization, and distribution of an unusual pancreatic human secretory protein. J Clin Invest. 1985; 76(6):2115-26. PMC: 424321. DOI: 10.1172/JCI112216. View

16.

Sjogren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E . The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord. 2001; 12(4):257-64. DOI: 10.1159/000051268. View

17.

Goedert M, Spillantini M, Potier M, Ulrich J, Crowther R . Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989; 8(2):393-9. PMC: 400819. DOI: 10.1002/j.1460-2075.1989.tb03390.x. View

18.

Arai H, Higuchi M, Morikawa Y, Miura M, Kawakami H, Seki H . No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci Lett. 1998; 256(3):174-6. DOI: 10.1016/s0304-3940(98)00781-2. View

19.

Tabaton M, Nunzi M, Xue R, Usiak M, Gambetti P . Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994; 200(3):1598-603. DOI: 10.1006/bbrc.1994.1634. View

20.

Hu Y, He S, Wang X, Duan Q, Grundke-Iqbal I, Iqbal K . Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002; 160(4):1269-78. PMC: 1867203. DOI: 10.1016/S0002-9440(10)62554-0. View